Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile

Date: October 29, 2014
Pages: 80
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RA06F31E283EN
Leaflet:

Download PDF Leaflet

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile
Summary

Rosetta Genomics, Ltd. (RGL) is a biotechnology company. The company discovers, develops and commercializes next generation diagnostic tests for personalized medicine. It provides testing services such as rosetta cancer origin test, resetta lung cancer test, rosetta kidney cancer test and rosetta mesothelioma test. RGL product pipeline includes tests such as thyroid neoplasia, oncology project, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company has distribution network in Australia, New Zealand, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. The company has its presence in the UA. RGL is headquartered in Rehovot, Israel.

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements: The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy: The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company: Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.: The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company: Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research: Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deal Details
Partnerships
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech
Rosetta Genomics Enters Into Licensing Agreement With Roche
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical
Rosetta Genomics Expands Distribution Agreement With Genekor
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services
Rosetta Genomics Enters Into Agreement With Carmel Medical Center
Rosetta Genomics Enters Into Distribution Agreement With Genekor
Rosetta Genomics Enters Into An Agreement With Genetic Technologies
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs
Warnex Signs Distribution Agreement With Rosetta Genomics
Teva Pharma Enters Into An Agreement With Rosetta Genomics
Rosetta Genomics Enters Into An Agreement With The University of Texas M. D. Anderson Cancer Center
Rosetta Genomics Enters Into Agreement With University Of California
Rosetta Genomics Enters Into Agreement With Henry Ford Health System
Prometheus Labs Signs An Agreement With Rosetta Genomics
Equity Offering
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million
Rosetta Genomics Completes Private Placement For US$2.7 Million
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million
Rosetta Genomics Completes Private Placement For US$2.5 Million
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million
Rosetta Genomics Completes Private Placement Of US$8 Million
Debt Offering
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million
Rosetta Genomics, Ltd. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Strategy And Business Planning
Sep 02, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics
Feb 18, 2014: Rosetta Genomics Executes Agreement With MultiPlan
Dec 12, 2013: Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology
Sep 09, 2013: Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Jun 04, 2013: Rosetta Genomics To Increase Number Of US Sales Territories
Financial Announcements
Sep 17, 2014: Rosetta Genomics Reports Financial Results for the First Half of 2014
Mar 31, 2014: Rosetta Genomics Reports 2013 Financial Results
Sep 10, 2013: Rosetta Genomics Reports Financial Results for the First Six Months of 2013
Corporate Communications
Aug 18, 2014: Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice President of Sales and Marketing
Feb 18, 2014: Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Legal and Regulatory
Apr 18, 2013: Rosetta Genomics Reaches Settlement Agreement With Sanra In Connection With Previous Sale Of Parkway
Government and Public Interest
Nov 27, 2013: Rosetta Genomics to Participate in the LD Micro Conference
Sep 25, 2013: Rosetta Genomics to Participate at the Aegis Capital 2013 Healthcare Conference
Sep 04, 2013: Rosetta Genomics to Host Business Update Conference Call on September 10, 2013
Product News
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test
Jul 10, 2014: Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer
Jun 09, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic
Dec 09, 2013: Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test
Jul 25, 2013: Rosetta Genomics Receives Notice of Allowance for Key U.S. Patent for the Rosetta Lung Cancer Test
Jun 13, 2013: Novitas Solutions Issues Final Local Coverage Determination For Rosetta Cancer Origin Test
Jun 07, 2013: Rosetta Genomics Executes Credentialing Agreement With TRPN For Rosetta Cancer Origin Test
Jun 06, 2013: Rosetta Genomics Announces Acceptance For Publication Of Rosetta Cancer Origin Test Manuscript Data In Molecular Cancer
May 20, 2013: Rosetta Genomics Executes Credentialing Agreement With Prime Health Services For miRview mets2
Apr 01, 2013: Rosetta Genomics Announces Acceptance For Publication Of Kidney Cancer microRNA Diagnostic Manuscript By Molecular Oncology
Feb 07, 2013: Rosetta Genomics Reports Data Demonstrating Ability Of microRNAs To Predict Progression Of Bladder Cancer
Product Approvals
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test
Dec 09, 2013: Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test
Other Significant Developments
Nov 20, 2013: Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania
Aug 05, 2013: Rosetta Genomics Announces Launch of New Website
May 10, 2013: Rosetta Genomics Gets Full Settlement Payment From Sanra Laboratories
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Rosetta Genomics, Ltd., Medical Equipment, Key Facts, 2013
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014
Rosetta Genomics, Ltd., Deals By Market, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech
Rosetta Genomics Enters Into Licensing Agreement With Roche
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical
Rosetta Genomics Expands Distribution Agreement With Genekor
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services
Rosetta Genomics Enters Into Agreement With Carmel Medical Center
Rosetta Genomics Enters Into Distribution Agreement With Genekor
Rosetta Genomics Enters Into An Agreement With Genetic Technologies
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs
Warnex Signs Distribution Agreement With Rosetta Genomics
Teva Pharma Enters Into An Agreement With Rosetta Genomics
Rosetta Genomics Enters Into An Agreement With The University of Texas M. D. Anderson Cancer Center
Rosetta Genomics Enters Into Agreement With University Of California
Rosetta Genomics Enters Into Agreement With Henry Ford Health System
Prometheus Labs Signs An Agreement With Rosetta Genomics
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million
Rosetta Genomics Completes Private Placement For US$2.7 Million
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million
Rosetta Genomics Completes Private Placement For US$2.5 Million
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million
Rosetta Genomics Completes Private Placement Of US$8 Million
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million
Rosetta Genomics, Ltd., Key Competitors
Rosetta Genomics, Ltd., Key Employees
Rosetta Genomics, Ltd., Other Locations
Rosetta Genomics, Ltd., Subsidiaries

LIST OF FIGURES

Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014
Rosetta Genomics, Ltd., Medical Equipment, Deals by Market, 2008 to YTD 2014
Skip to top


Ask Your Question

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: